Cyclosporine Ophthalmic

Major

Cyclosporine Ophthalmic Terbinafine Lamisil Reduced cycloSPORINE exposure and a reduced therapeutic response to cycloSPORINE Details Cyclosporine Ophthalmic Tezacaftor Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Cyclosporine Ophthalmic Thioridazine Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Tiaprofenic Acid An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Ticagrelor Brilinta Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Ticlopidine Ticlid® Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Cyclosporine Ophthalmic Tobramycin Bethkis An increased risk of renal dysfunction or nephrotoxicity Details Cyclosporine Ophthalmic Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Cyclosporine Ophthalmic Tofacitinib Xeljanz Increased risk of immunosuppression Details Cyclosporine Ophthalmic Tolfenamic Acid An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Tolmetin Tolectin 600 An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Tolvaptan Jynarque Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Topotecan Hycamtin Increased topotecan exposure and risk of adverse events Details Cyclosporine Ophthalmic Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Cyclosporine Ophthalmic Tramadol ConZip Increased traMADol exposure and an increased risk of seizures, serotonin syndrome and opioid toxicity Details Cyclosporine Ophthalmic Trandolapril Mavik® Acute renal dysfunction and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Cyclosporine Ophthalmic Triamterene Dyrenium An increased risk of hyperkalemia Details Cyclosporine Ophthalmic Trimethoprim Primsol Increased nephrotoxicity and an increased risk of renal dysfunction Details Cyclosporine Ophthalmic Trofinetide Daybue Increased sensitive CYP3A/P-gp substrate with NTI exposure and an increased risk of sensitive CYP3A/P-gp substrate with NTI substr... Details Cyclosporine Ophthalmic Troleandomycin Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Cyclosporine Ophthalmic Typhoid Vaccine, Live Vivotif An inadequate immunological response to the vaccine, increased risk of disseminated infection with live vaccines and reduced effic... Details Cyclosporine Ophthalmic Ubrogepant Ubrelvy Increased ubrogepant exposure Details Cyclosporine Ophthalmic Ustekinumab Altered cycloSPORINE exposure Details Cyclosporine Ophthalmic Valdecoxib An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Valsartan Diovan Increased valsartan exposure and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Vancomycin Firvanq Increased risk of renal dysfunction Details Cyclosporine Ophthalmic Vandetanib Caprelsa Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Varicella Virus Vaccine, Live An inadequate immunological response to the vaccine, increased risk of disseminated infection with live vaccines and reduced effic... Details Cyclosporine Ophthalmic Velpatasvir Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Vemurafenib Zelboraf Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Venetoclax Venclexta Increased cycloSPORINE exposure, increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk o... Details Cyclosporine Ophthalmic Venlafaxine Increased venlafaxine exposure and its active metabolite and risk of venlafaxine-associated toxicity Details Cyclosporine Ophthalmic Vepdegestrant Veppanu Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Cyclosporine Ophthalmic Verapamil Calan An increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Vibegron Gemtesa Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Vilazodone Viibryd Increased P-gp substrate exposure Details Cyclosporine Ophthalmic Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Cyclosporine Ophthalmic Voclosporin Lupkynis Increased cycloSPORINE exposure Details